Moleculin Biotech, Inc.
NCM: MBRXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Moleculin Biotech, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get MBRX Z-Score →About Moleculin Biotech, Inc.
Healthcare
Biotechnology
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.
📊 Fundamental Analysis
Moleculin Biotech, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -256.0%, which indicates that capital utilization is currently under pressure.
At a current price of $2.62, MBRX currently trades near the bottom of its 52-week range (3%), indicating potential value or weakness (Range: $1.79 - $28.60).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$13.98M
Trailing P/E
--
Forward P/E
-0.02
Beta (5Y)
1.67
52W High
$28.60
52W Low
$1.79
Avg Volume
160K
Day High
Day Low